Tests a GnRH agonist before frozen embryo transfer in endometriosis or adenomyosis
Tests a GnRH agonist drug added before embryo transfer in women with endometriosis or adenomyosis.
Plain-language title generated from the registry record
Registry title: Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis
Key facts
- Where
- Suresnes, FranceSee the site
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 36 years old?
Source: NCT04356664, who can take part
Where in France
- Hospital FochSuresnes, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hopital Foch
- Trial code
- NCT04356664EU 2024-519126-20-00
- Record updated
- 16 January 2026
- Original description
Women suffering from endometriosis and/or adenomyosis may also suffer from infertility. GnRH agonist injection could improve implantation and therefore increase the pregnancy rate in these patients. This study was designed to evaluate effects of the additional of GnRH agonist (single or 2 doses) to the routine oestrogens and progestins use as support before Frozen Embryon Transfer as compared to oestrogens and progestins only.Read full original descriptionShow less
Benefit of Gonadotropin-releasing Hormone (GnRH) Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and / or Adenomyosis: Randomized Prospective Study
Women suffering from endometriosis and/or adenomyosis may also suffer from infertility. GnRH agonist injection could improve implantation and therefore increase the pregnancy rate in these patients. This study was designed to evaluate effects of the additional of GnRH agonist (single or 2 doses) to the routine oestrogens and progestins use as support before Frozen Embryon Transfer as compared to oestrogens and progestins only.
Inclusion: Women aged 18 to 36 years (women ≥18 years to <36 years) with endometriosis and / or adenomyosis; Having benefited from In vitro fertilisation /intracytoplasmic micro-injection with freeze all and for whom the frozen embryon transfer of a blastocyst is planned; A normal uterine cavity; An MRI showing endometriosis and / or adenomyosis during the inclusion visit; Having signed a consent form; Being affiliated to a Health Insurance Plan.
Exclusion: GnRH Agonist Decapeptyl administered within 6 months prior to transfer; History of implantation failures (≥ 2); Hypersensitivity to GnRH, GnRH analogues, or any of the excipients of Decapeptyl 3 mg; Known hypersensitivity to estradiol; Known hypersensitivity to progesterone; Known hypersensitivity to acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs; Known hypersensitivity to folic acid; Known hypersensitivity to cefixime or an antibiotic in the cephalosporin group; Known hypersensitivity to levofloxacin or any other quinolone; History of tendinopathies related to the administration of fluoroquinolones; Epilepsy; Hypersensitivity to contrast agents for MRI; Known or suspected breast cancer or history of breast cancer; Known or suspected genital tract cancer or history of genital cancer; known or suspected estrogen-dependent malignant neoplasms; Undiagnosed genital haemorrhage; History of idiopathic venous thrombo-embolic accident or evolving venous thrombo-embolic event (deep vein thrombosis, pulmonary embolism); Recent or evolving arterial thromboembolic stroke (eg angina, myocardial infarction); Acute liver disease or history of liver disease, until hepatic tests are normalized; Severe renal insufficiency; Severe, uncontrolled heart failure; Evolutionary gastroduodenal ulcer; History of asthma caused by the administration of salicylates or substances of similar activity, especially nonsteroidal anti-inflammatory drugs; Patient aged <18 years and ≥ 36 years; BMI> 35; Endometrial alterations: synechiae, polyps, myomas, hyperplasia, hematometra; known hydrosalpinx uni or bilateral; MRI showing no endometriosis or adenomyosis; Untreated endometrial hyperplasia; To be deprived of liberty or under guardianship; Pregnancy and breast feeding.